![]() ![]() In particular, he notes the ability of Genexus™ to detect a broad range of genomic variants, including both mutations and amplifications – and, by way of illustration, cites the example of ERBB2 mutations in colon adenocarcinoma. Leomar emphasizes the platform’s advantages over competing technologies such as fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC). Detection sensitivities were particularly encouraging in SNV screens, with 75 percent of SNVs detected at a MAF of 2.5 percent (see Figure 1).īut Genexus™ has other favorable attributes too. The results were excellent at 5 percent minimal allelic frequency (MAF), the Genexus™-Oncomine system detected 100 percent of variants. In brief, the team assayed SNVs, CNVs, and fusions with reference to standard commercial controls. How robust is the Genexus™ Sequencer in the face of these goals and constraints? To address this question, Leomar Ballester assigned a small team (three individuals) to screen FFPE tissue samples using the Genexus™ Sequencer in combination with the Oncomine Precision Assay. ![]() Today’s laboratories must provide accurate results as quickly as possible – often with strictly limited personnel numbers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |